title: Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
abstract: OBJECTIVE
  To compare the efficacy and safety of paclitaxel liposome (Lipusu®) with paclitaxel in combination with tegafur and oxaliplatin in treating patients with advanced gastric cancer.
  
  
  METHODS
  Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups. Patients in group A received paclitaxel liposomes at a dose of 135 mg/m2 on day 1 of each cycle, and patients in group B were given paclitaxel at the same dose with the same timing. All patients received tegafur at a dose of 500 mg mg/m2 on days 1-5, and oxaliplatin at a dose of 80-100 mg/m2 on day 1 for 2 cycles (each cycle was 21 d in total).
  
  
  RESULTS
  Fifty-eight patients could be evaluated for efficacy. The overall response rate was 47% in group A (14/30), and 46% in group B (13/28). Disease control rate was 73% in group A (22/30), and 71% in group B (20/28) (P>0.05). No significant differences were detected in hematologic and neurologic toxicities between the two groups (P>0.05). However, nausea, vomiting and hypersensitive reactions were significantly lower in group A than in group B (P<0.05).
  
  
  CONCLUSIONS
  Paclitaxel liposomes are as effective as paclitaxel when combined with tegafur and oxaliplation in treating patients with advanced gastric cancer, but adverse reactions with paclitaxel liposomes are less common.
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Nanjing, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Xu
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Huan-Qin
authors.initials: HQ
authors.lastname: Xu
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Ya-Dong
authors.initials: YD
authors.lastname: Qian
authors.forename: Jin
authors.initials: J
authors.lastname: Xiang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D008081:Liposomes; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005641:Tegafur; D017239:Paclitaxel; D005472:Fluorouracil